Assessment of pathologic interpretation of colorectal polyps by general pathologists in community practice Bernard DENIS, Carol PETERS, Catherine CHAPELAIN,

Slides:



Advertisements
Similar presentations
A guaiac- based faecal occult blood colorectal cancer screening program involving general practitioners is feasible and cost-effective for mass population.
Advertisements

Polyps – Where do they come from and what do you do with them?!
Management of Malignant Polyps Santhat Nivatvongs, MD Colon and Rectal Surgery Mayo Clinic Rochester Minnesota U.S.A.
Organized colorectal cancer screening program with FOBT: participation and diagnostic yield deteriorate with time Results – yield Aim To assess the short.
Role of colonoscopy in the treatment of malignant polyps Pathology of malignant colorectal polyps Assessing the risk of residual disease post-polypectomy.
Treatment of large and giant colorectal polyps in the real world Stéphanie HUSSON, Guy VENTRE, Frédéric VAGNE, Jean François VIES, Marjorie MUSSO, Jean.
Colorectal Adenomas Santhat Nivatvongs MD Mayo Clinic Rochester Minnesota U. S.A.
Colorectal NSSG Audit Day - Polyp Cancers Northumbria Healthcare NHS Trust Sarah Mills.
Long-Term Colorectal-Cancer Incidence and Mortality after Lower Endoscopy Supervisor: 邱宗傑 主任 Presented by 郭政裕 總醫師 NEJM, Sep 19, 2013.
The Adenoma/Carcinoma Sequence in the Colon
Assessment of Adenomas Geraint Williams Pathology Department Cardiff University.
A re-audit of Prostate biopsies from January to December 2010 and Dr. M S Siddiqui Consultant Histopathologist University Hospital of North Tees.
Surveillance colonoscopy after polypectomy – how frequent? Dr Chu Ming Leong Tuen Mun Hospital 1.
Is upper endoscopy indicated in persons with a positive FOBT and a negative colonoscopy in a population-based colorectal cancer screening program ? Bernard.
Adverse effects of colorectal cancer screening with fecal occult blood test: a population-based organized program Results – serious adverse effects Adverse.
Cancer -Screening -Grading -Breast + GI cancers Vivian Phan.
Joint Hospital Surgical Grand Round 19 June 2004.
Reporting and Management of Early stage Colorectal Cancer Frank Carey Dundee.
Colorectal cancer Khayal AlKhayal MD,FRCSC
Bowel Screening in Scotland – Current Challenges and Possible Solutions Prof. Bob Steele Ninewells Hospital, University of Dundee.
Treatment of Early Malignant Rectal Polyp
1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.
Validation of a Simple Classification System for Endoscopic Diagnosis of Small Colorectal Polyps Using Narrow-Band Imaging David G. Hewett GASTROENTEROLOGY.
High risk population in GI field how we can find them? Ahmad Shavakhi MD Associate professor of gastroenterology.
Colorectal cancer screening by primary care physicians: a prospective chart audit Bernard DENIS, Guillaume SCHON, Marcel RUETSCH, Jean Christian GRALL,
TREATMENT OF LARGE AND GIANT COLORECTAL POLYPS IN THE REAL WORLD UEGW, PARIS, 2007 Association pour le Dépistage du Cancer colorectal dans le Haut-Rhin.
Colorectal carcinoma Dr.Mohammadzadeh.
© Copyright Annals of Internal Medicine, 2014 Ann Int Med. 160 (5): ITC5-1. * For Best Viewing: Open in Slide Show Mode Click on icon or From the View.
Colorectal cancer Khayal AlKhayal MD,FRCSC Assistant professor of Surgery Consultant Colorectal surgeon 9/11/2015Shwartz.
CONFIDENTIAL PillCam ™ COLON PillCam™ COLON has received a CE Mark, but is not cleared for marketing or available for commercial distribution in the USA.
Slides last updated: June 2015 CRC: CLINICAL FEATURES.
Results and cost of a population-based biennial faecal occult blood colorectal cancer screening program Bernard DENIS, Philippe PERRIN, Jean François VIES,
Handling difficult cases and possible referral service Professor Neil A Shepherd Gloucester, UK NHSBCSP Pathology Day, London, November 21, 2007.
Management of Serrated Polyps of Colorectum Eric YF Cheung Department of Surgery, NDH.
Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based fecal occult blood testing: a population-based controlled trial.
SETTING UP THE SERVICE BY LYNN TOBIN. HOW DID WE GET HERE? ABUNDENCE OF EVIDENCE PROVIDING JUSTIFICATION FOR BOWEL CANCER SCREENING.
A National Bowel Screening Programme Anticipated Colonoscopy Volumes Susan Parry Gastroenterologist, Clinical Director, MOH Bowel Cancer Programme Emmanuel.
Colon polyps Peter Stanich, MD
Incorporating Multiple Evidence Sources for the Assessment of Breast Cancer Policies and Practices J. Jackson-Thompson, Gentry White, Missouri Cancer Registry,
Modeling Efforts to Inform Countries’ Screening Decisions Ann Graham Zauber, Iris Vogelaar, Marjolein van Ballegooijen, Deb Schrag, Rob Boer, Dik Habbema,
Serrated Polyps of the Colon Aaron Sinclair, MD University of Kansas School of Medicine – Wichita Department of Family and Community Medicine Wesley Family.
Colonic cancer screening in high risk groups
LCC REC-1 Φ π π π Φ Φ See Primary and Adjuvant Treatment (LCC REC-3) Observe or See Primary Treatment (LCC REC-3) Rectal Cancer.
Yield of colonoscopy for advanced neoplasia in a population-based setting Bernard DENIS, Jacques PICOT, Jean François VIES, Marjorie MUSSO, Paul François.
NHSBCSP - guidelines Phil Quirke. Why guidelines To meet the needs of the programme To improve outcomes To increase the knowledge base and evolve pathology.
Do all colorectal polyps require pathological examination? Aim To assess whether it is possible to omit the pathological examination of some polyps without.
CT Colonography vs Colonoscopy for the Detection of Advanced Neoplasia David H. Kim, M.D., Perry J. Pickhardt, M.D., Andrew J. Taylor, M.D., Winifred K.
LCC COL-1 See Pathologic Stage, Adjuvant Therapy, and Surveillance (LCC COL-3) Φ Φ Φ π π π Colon Cancer.
First results of a pilot population-based faecal occult blood colorectal cancer screening program B. DENIS, P. PERRIN, J.F. EBELIN, P. WEBER, E. KALTENBACH,
Colorectal Cancer Screening – 2016 Update Howard Zhang, MD Chief of Gastroenterology and Hepatology Summa Health System.
Pancreatic endoscopy : ROLE Of Endo TOF PET US Pr. René LAUGIER La Timone Hospital,Marseille MEDAMI Alghero, 4 th September 2014.
Interval Colorectal Cancer 전임의 남지혁 Comparison of the Observed Incidence of Colorectal Cancer in the National Polyp Study Cohort with That.
Assessing Quality of Pathology Reporting: The Case of Tongue Cancer Lihua Liu 1, PhD Wesley Y. Naritoku 2, MD, PhD Juanjuan Zhang 1, MS Lenard Berglund.
The Malignant Polyp Handout Version Hans Elzinga, MD Program Director- Advanced Procedures in Family Medicine Fellowship Salud Family Health Center-Longmont,
Gastroenterological Society of Queensland Young Investigator Awards The Traditional Serrated Adenoma A Clinicopathological and Molecular Analysis Presented.
Am J Gastroenterol 2012; 107:1213– June 2012 R3. 김동희 /prof. 이창균.
Colonoscopic Polypectomy and Long-Term Prevention of Colorectal- Cancer Deaths N ENG J MED ;8 : Ann G. Zauber, Ph.D, Sidney J. Winawer,
Jasper Vleugels PhD-student AMC
Repeat Colonoscopy Recommendations
A Visual Tour of Effective Colonoscopy
Douglas K. Rex, Emely Eid  Clinical Gastroenterology and Hepatology 
Improving Quality Measures for Colonoscopy and CRC Prevention
Feeling Rushed? Does Late Start Time Predict Poor Quality Colonoscopy?
A Visual Tour of Effective Colonoscopy
Cesare Hassan, Perry J. Pickhardt, Douglas K. Rex 
Colorectal cancer screening: Recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer  Douglas K. Rex,
Volume 133, Issue 4, Pages (October 2007)
Hyperplastic polyps and colorectal cancer: is there a link?1
Projected National Impact of Colorectal Cancer Screening on Clinical and Economic Outcomes and Health Services Demand  Uri Ladabaum, Kenneth Song  Gastroenterology 
Presentation transcript:

Assessment of pathologic interpretation of colorectal polyps by general pathologists in community practice Bernard DENIS, Carol PETERS, Catherine CHAPELAIN, Isabelle KLEINCLAUS, Anne FRICKER, Richard WILD, Bernard AUGE, Denis CHATELAIN, Jean François FLEJOU Association pour le dépistage du cancer colorectal dans le Haut-Rhin (ADECA 68) Colmar, France

B. Denis - DDW 2007 – Washington DC background l The assessment of type and dysplasia of colorectal polyps is poorly reproducible in clinical practice Demers RY 1990, Jensen P 1995, Rex DK 1999, Yoon H 2002, Costantini M 2003, Komuta K 2004

B. Denis - DDW 2007 – Washington DC background l population-based CRC screening program with guaiac based FOBT l Haut-Rhin: u 1 of 23 pilot areas u residents aged y l May 2006: 2560 polyps / 1274 people

B. Denis - DDW 2007 – Washington DC background P<0.001 Rate of adenomas with >20% villous elements. Goal: <10% Recommendations U.S. multi-society task force on CRC. Am J Gastroenterol 2002

B. Denis - DDW 2007 – Washington DC aim to assess l performances of community pathologists in the interpretation of colorectal polyps l clinical impact on a population-based FOBT CRC screening program

B. Denis - DDW 2007 – Washington DC methods l screening program 2560 polyps = whole cohort slides / 14 community pathologists (P1) l study u sample of 300 polyps (11.7%) all serrated adenomas (n = 71) all in situ (n = 77) and T1 carcinomas (n = 39) other polyps selected at random (n = 114) u review sslides / 2 expert GI academic pathologists (P2) spathology reports of malignant polyps

B. Denis - DDW 2007 – Washington DC results – study population histology sample P2 n = 292 n (%) adenomatous polyps192 (65.8) tubular60 (20.5) tubulovillous122 (41.8) villous10 (3.4) serrated polyps98 (33.6) hyperplastic77 (26.4) serrated ad. + SSA14 (4.8)

B. Denis - DDW 2007 – Washington DC results – study population histology sample P2 n = 292 n (%) whole cohort P1 n = 2368 n (%) p adenomatous polyps192 (65.8)1833 (77.4)< tubular60 (20.5)1331 (56.2)< tubulovillous122 (41.8)456 (19.3)< villous10 (3.4)46 (1.9)NS serrated polyps98 (33.6)468 (19.8)< hyperplastic77 (26.4)393 (16.6)< serrated ad. + SSA14 (4.8)75 (3.2)NS

B. Denis - DDW 2007 – Washington DC results – community pathologists performances histology agreement 300 polyps (%) sensitivity 300 polyps (%) specificity 300 polyps (%) adenomatous polyps serrated polyps

B. Denis - DDW 2007 – Washington DC histology agreement 300 polyps (%) sensitivity 300 polyps (%) specificity 300 polyps (%) >20% villous elements hyperplastic serrated adenomas results – community pathologists performances

B. Denis - DDW 2007 – Washington DC clinical impact l 2 questions to the pathologist u is the polyp malignant? if yes, is surgery needed? u is colonoscopic surveillance needed? if yes, when? no 5 y3 y yes

B. Denis - DDW 2007 – Washington DC results – clinical impact 261 benign polyps ≥ 10 mm< 10 mm disagreement with impact6.1%58.4% over surveillance6.1%54.0% under surveillance0%4.4%

B. Denis - DDW 2007 – Washington DC results – clinical impact 261 benign polyps ≥ 10 mm< 10 mm disagreement with impact6.1%58.4% over surveillance6.1%54.0% under surveillance0%4.4%

B. Denis - DDW 2007 – Washington DC results – clinical impact 36 malignant polyps n (%) disagreement with impact11 (25.6) over treatment7 (16.3) under treatment4 (9.3)

B. Denis - DDW 2007 – Washington DC Bayes formulae PPV = Se x P NPV = Sp x (1 - P) Se x P + (1 - P) x (1 - Sp) Sp x (1 - P) + P x (1 – Se) PPV whole cohort NPV whole cohort T1 carcinoma34.9%99.8% results – community pathologists performances

B. Denis - DDW 2007 – Washington DC results – overall clinical impact whole cohort agreement45.2% disagreement without impact27.5% disagreement with impact27.2%

B. Denis - DDW 2007 – Washington DC results – pathology reports of malignant polyps

B. Denis - DDW 2007 – Washington DC conclusion l poor inter-observer agreement in the pathologic interpretation of colorectal polyps by community pathologists l in the real world, impact on clinical management: 1/4 of cases l frequent lack of adequate characterization of malignant polyps

B. Denis - DDW 2007 – Washington DC future l benign polyps u need for a clarification (simplification) of the nomenclature, especially for serrated polyps u surveillance interval for polyps ≥ 10 mm should be 3 years whatever the pathology report may be l malignant polyps u slides should be reviewed by expert pathologists u need for a standardized pathology report

B. Denis - DDW 2007 – Washington DC standardized pathology report for malignant polyps degree of differentiation: …….. angiolymphatic invasion: ……… resection margin status: ……… T stage: ……….

B. Denis - DDW 2007 – Washington DC acknowledgements l Bernard Auge l Catherine Chapelain l Anne Fricker l Sylvette Itten l Isabelle Kleinclaus l Sylvie Krzisch l Denis Laedlein l Carol Peters l Martine Prevot l Sylvie Rozan l Pierre Straub l Sylvie Thiebault l Marie Claire Tortel l Richard Wild